Smartlab Europe

Clinical Trials

OTEZLA (Apremilast) Phase III Data Showed good results among Patients with Active Behçet’s Disease with Oral Ulcers

Celgene Corporation announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet's Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD)...

Indian Government to come out with a new pharma policy

The government is looking to bring in a new pharma policy for implementing the proposed healthcare plan across the country in the next couple of months, Union Chemicals and Fertilisers Minister Ananth Kumar said today. "We...

Flex Databases is Beginning to Implement Blockchain Technology in Our IT Systems That Manage Clinical Trial Studies

The past few years have created something of a boom in the development of Blockchain technology and its emerging applications within various industries and spheres of life. Following our strategic policy of continuous improvement and the...

ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC

ZZ Biotech announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented at the 2018 International Stroke Conference in Los Angeles. The placebo-controlled dose-escalation trial was designed...

Araclon Biotech Partners with TFS International for Their Alzheimer’s Phase II Trial

After completing a successful phase I partnership with TFS International (TFS), Araclon Biotech a Grifols company, decided to continue the partnership with TFS advancing their Alzheimer’s disease (AD) vaccine ABvac40 into phase II.  The placebo-controlled phase...

Biohaven to begin clinical development of BHV-5000 to treat Rett syndrome

Biohaven Pharmaceutical Holding Company Ltd. and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. FDA has notified the Company that it may proceed with its clinical investigation of BHV-5000.  Enrollment of subjects...

BioNTech Announces Results from Two More Studies Demonstrating the Benefits of Breast Cancer Subtyping Using Mammatype

BioNTech Diagnostics GmbH is announcing new results from two studies on the MammaTyper® test which were presented at the Breast Cancer Symposium in San Antonio in December.1,2 The results of these studies again demonstrate the benefits...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »